دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Moving Beyond “Until Saturation Was Reached”: Critically Examining How Saturation Is Used and Reported in Qualitative Research
Jenny Leese,Linda C. Li,Laura Nimmon,Anne F. Townsend,Catherine L. Backman,
doi : 10.1002/acr.24600
Volume 73, Issue 9 p. 1225-1227
A Defined Problem: Working Toward a Clinical Definition of Foot Osteoarthritis
Kade L. Paterson,John B. Arnold,
doi : 10.1002/acr.24594
Volume 73, Issue 9 p. 1228-1230
Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria
Michelle Petri,Daniel W. Goldman,Graciela S. Alarcón,Caroline Gordon,Joan T. Merrill,Paul R. Fortin,Ian N. Bruce,David Isenberg,Daniel Wallace,Ola Nived,Rosalind Ramsey-Goldman,Sang-Cheol Bae,John G. Hanly,Jorge Sanchez-Guerrero,Ann E. Clarke,Cynthia Aranow,Susan Manzi,Murray Urowitz,Dafna D. Gladman,Ken Kalunian,Victoria P. Werth,Asad Zoma,Sasha Bernatsky,Munther Khamashta,Søren Jacobsen,Jill P. Buyon,Mary Anne Dooley,Ronald van Vollenhoven,Ellen Ginzler,Thomas Stoll,Christine Peschken,Joseph L. Jorizzo,Jeffery P. Callen,Sam Lim,Murat Inanç,Diane L. Kamen,Anisur Rahman,Kristjan Steinsson,Andrew G. Franks Jr,Laurence S. Magder,
doi : 10.1002/acr.24263
Volume 73, Issue 9 p. 1231-1235
The Systemic Lupus International Collaborating Clinics (SLICC) 2012 systemic lupus erythematosus (SLE) classification criteria and the revised American College of Rheumatology (ACR) 1997 criteria are list based, counting each SLE manifestation equally. We derived a classification rule based on giving variable weights to the SLICC criteria and compared its performance to the revised ACR 1997, the unweighted SLICC 2012, and the newly reported European Alliance of Associations for Rheumatology (EULAR)/ACR 2019 criteria sets.
Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries With Lupus
Candace H. Feldman,Chang Xu,Karen H. Costenbader,
doi : 10.1002/acr.24628
Volume 73, Issue 9 p. 1236-1242
Nearly 25% of patients with systemic lupus erythematosus (SLE) are hospitalized yearly, often for outcomes that may have been avoided if patients had received sustained outpatient care. We examined acute care use for vaccine-preventable illnesses to determine sociodemographic contributors and modifiable predictors.
Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index
Zahi Touma,Dafna D. Gladman,Moe Zandy,Jiandong Su,Nicole Anderson,Murray B. Urowitz,
doi : 10.1002/acr.24261
Volume 73, Issue 9 p. 1243-1249
To compare the performance of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and the SLEDAI-2K Glucocorticoids (SLEDAI-2KG) indices in identifying responders to standard of care therapy.
Association of Dietary Quality With Risk of Incident Systemic Lupus Erythematosus in the Nurses’ Health Study and Nurses’ Health Study II
Medha Barbhaiya,Sara Tedeschi,Jeffrey A. Sparks,Cianna Leatherwood,Elizabeth W. Karlson,Walter C. Willett,Bing Lu,Karen H. Costenbader,
doi : 10.1002/acr.24443
Volume 73, Issue 9 p. 1250-1258
Knowledge remains scarce regarding diet and systemic lupus erythematosus (SLE) risk. Our objective was to investigate 4 dietary quality scores and SLE risk overall and by anti–double-stranded DNA (anti-dsDNA) positive versus negative subtypes.
Methotrexate in Linear Scleroderma: Long-Term Efficacy in Fifty Children From a Single Pediatric Rheumatology Center
Gloria Fadanelli,Anna Agazzi,Fabio Vittadello,Alessandra Meneghel,Francesco Zulian,Giorgia Martini,
doi : 10.1002/acr.24260
Volume 73, Issue 9 p. 1259-1263
To study disease course and long-term outcome in children with linear scleroderma (SSc) treated with methotrexate (MTX) since diagnosis.
Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis
Hermine I. Brunner,Chen Chen,Francesca Bovis,Fabrizio De Benedetti,Graciela Espada,Rik Joos,Jonathan Akikusa,Jeffrey Chaitow,Alina Lucica Boteanu,Yukiko Kimura,Christoph Rietschel,Daniel Siri,Elzbieta Smolewska,Heinrike Schmeling,Diane E. Brown,Alberto Martini,Daniel J. Lovell,Bin Huang,Nicolino Ruperto,for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group,
doi : 10.1002/acr.24384
Volume 73, Issue 9 p. 1264-1274
To evaluate changes in health-related quality of life (HRQoL) and disability in children with systemic juvenile idiopathic arthritis (JIA) or polyarticular JIA treated with tocilizumab.
Early Joint Replacement in Juvenile Idiopathic Arthritis: Trend Over Time and Factors Influencing Implant Survival
Achille Marino,Irene Pontikaki,Marcello Truzzi,Alessandra Menon,Carolina Artusi,Marco Di Marco,Pietro S. Randelli,Rolando Cimaz,Roberto Viganò,
doi : 10.1002/acr.24337
Volume 73, Issue 9 p. 1275-1281
To describe early prosthesis implantations in a cohort of patients with juvenile idiopathic arthritis (JIA) followed in a tertiary referral hospital and to analyze possible factors influencing implant survival.
Understanding Fatigue-Related Disability in Rheumatoid Arthritis and Ankylosing Spondylitis: The Importance of Daily Correlates
Roisin S. M. Hegarty,Tamlin S. Conner,Simon Stebbings,Benjamin D. Fletcher,Andrew Harrison,Gareth J. Treharne,
doi : 10.1002/acr.24224
Volume 73, Issue 9 p. 1282-1289
Fatigue is common among people with inflammatory arthritis but is hard to manage. The aim of this study was to investigate how daily fluctuations in psychological variables correspond with changes in fatigue-related disability in the daily lives of people with inflammatory arthritis and to identify factors to target in psychological interventions and routine clinical practice.
Measuring Inflammatory Foot Disease in Rheumatoid Arthritis: Development and Validation of the Rheumatoid Arthritis Foot Disease Activity Index–5
Anika Hoque,Kellie Gallagher,Anne McEntegart,Duncan Porter,Martijn Steultjens,James Woodburn,Gordon J. Hendry,
doi : 10.1002/acr.24259
Volume 73, Issue 9 p. 1290-1299
Omission of foot joints from composite global disease activity indices may lead to underestimation of foot and overall disease in rheumatoid arthritis (RA) and under-treatment. The aim of this study was to evaluate the measurement properties of the Rheumatoid Arthritis Foot Disease Activity Index–5 (RADAI-F5), a newly developed patient-reported outcome measure for capturing foot disease activity in people with RA.
Patient Global Assessment of Disease Activity and Radiographic Progression in Early Arthritis: Three-Year Results From the ESPOIR Cohort
Ricardo J. O. Ferreira,Bruno Fautrel,Alain Saraux,Cécile Gaujoux-Viala,Anne-Christine Rat,Francis Guillemin,José A. P. da Silva,Maxime Dougados,Laure Gossec,
doi : 10.1002/acr.24237
Volume 73, Issue 9 p. 1300-1305
To determine whether patient global assessment of disease activity (PtGA) over the first year of disease course, as part of a Boolean-based definition of remission and considered individually, had a significant relationship with structural progression over 3 years in patients with early arthritis.
Safety and Tolerability of Subcutaneous Methotrexate in Routine Clinical Practice
Christien K. H. Li,Kenneth Baker,Tania Jones,Elizabeth Coulson,Andrew Roberts,Fraser Birrell,
doi : 10.1002/acr.24334
Volume 73, Issue 9 p. 1306-1311
To show the safety and efficacy of subcutaneous (SC) methotrexate (MTX) compared to oral MTX, alternative disease-modifying antirheumatic drugs (DMARDs) monotherapy, biologic monotherapy, and combinations (conventional and biologic combination groups) in routine clinical practice.
Pain Over Two Years After Start of Biologic Versus Conventional Combination Treatment in Early Rheumatoid Arthritis: Results From a Swedish Randomized Controlled Trial
Tor Olofsson,Johan K. Wallman,Anna Jöud,Maria E. C. Schelin,Sofia Ernestam,Ronald van Vollenhoven,Saedis Saevarsdottir,Jon Lampa,
doi : 10.1002/acr.24264
Volume 73, Issue 9 p. 1312-1321
To compare the pain course between methotrexate (MTX)-refractory early rheumatoid arthritis (RA) patients randomized to infliximab (IFX) versus sulfasalazine (SSZ) plus hydroxychloroquine (HCQ).
Changes in Disease-Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A Three-Month Observational Study
Kaleb Michaud,Sofia Pedro,Kristin Wipfler,Ekta Agarwal,Patricia Katz,
doi : 10.1002/acr.24611
Volume 73, Issue 9 p. 1322-1331
To understand medication, lifestyle, and clinical care changes of persons with rheumatoid arthritis (RA) during the first months (March 2020 through May 2020) of the COVID-19 pandemic in the US.
Ultrasound Detection of Calcinosis and Association With Ulnar Artery Occlusion in Patients With Systemic Sclerosis
Robert Fairchild,Melody Chung,Laurel Sharpless,Shufeng Li,Lorinda Chung,
doi : 10.1002/acr.24327
Volume 73, Issue 9 p. 1332-1337
To investigate the ability of ultrasound (US) compared to radiographs to detect calcinosis in hands/wrists of patients with systemic sclerosis (SSc), and to assess US markers of pathologic perfusion.
Development and Assessment of Novel Lung Ultrasound Interpretation Criteria for the Detection of Interstitial Lung Disease in Systemic Sclerosis
Robert Fairchild,Melody Chung,Diana Yang,Laurel Sharpless,Shufeng Li,Lorinda Chung,
doi : 10.1002/acr.24338
Volume 73, Issue 9 p. 1338-1342
Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc), and ILD screening, characterization, and monitoring are important for therapeutic decision-making and prognostication. Lung ultrasonography (US) is a potential alternative imaging modality for ILD detection. In this study, our objective was to develop and test a novel lung US examination technique and interpretation criteria for detecting SSc-ILD.
Factors Associated With Functional Decline in Hand and Hip/Knee Osteoarthritis After One Year: Data From a Population-Based Study
Paola Siviero,Federica Limongi,Antonella Gesmundo,Sabina Zambon,Cyrus Cooper,Elaine M. Dennison,Mark H. Edwards,Suzan van der Pas,Erik J. Timmermans,Natasja M. van Schoor,Laura A. Schaap,Dhayana Dallmeier,Michael D. Denkinger,Richard Peter,Maria Victoria Castell,Ángel Otero,Nancy L. Pedersen,Dorly J. H. Deeg,Stefania Maggi,for the European Project on Osteoarthritis Research Group,
doi : 10.1002/acr.24404
Volume 73, Issue 9 p. 1343-1353
To investigate factors that together with hand or hip/knee osteoarthritis (OA) could contribute to functional decline over a year’s time in elderly individuals.
Trajectories of Structural Disease Progression in Knee Osteoarthritis
Jamie E. Collins,Tuhina Neogi,Elena Losina,
doi : 10.1002/acr.24340
Volume 73, Issue 9 p. 1354-1362
Knee osteoarthritis (OA) is a heterogeneous disease, with most patients experiencing slow disease progression and some with rapid deterioration. We aimed to identify groups of patients with symptomatic knee OA experiencing rapid structural progression.
Incidence, Prevalence, and Burden of Gout in the Veterans Health Administration
Lindsay N. Helget,Bryant R. England,Punyasha Roul,Harlan Sayles,Alison D. Petro,Kaleb Michaud,Ted R. Mikuls,
doi : 10.1002/acr.24339
Volume 73, Issue 9 p. 1363-1371
To determine the prevalence, incidence, and burden of gout in the Veterans Health Administration (VHA) from 2005 to 2014.
Long-Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis
Peter A. Merkel,John L. Niles,Lester E. Mertz,Patricia B. Lehane,Pooneh Pordeli,Félix Erblang,
doi : 10.1002/acr.24332
Volume 73, Issue 9 p. 1372-1378
The present study was undertaken to conduct a phase IV, open-label, prospective study to characterize the long-term safety of rituximab in a 4-year observational registry of adult patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) within the US.
